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Abstract
Background: Mutations in STOX1 were proposed to be causal for predisposing to preeclampsia, a hypertensive disorder
originating from placental defects, affecting up to 10% of human pregnancies. However, after the first study published in
2005 three other groups have dismissed the polymorphism described in the first paper as a causal mutation.
Methodology and Principal Findings: In the present study, we have produced a choriocarcinoma cell line overexpressing
STOX1. This overexpression results in transcriptional modification of 12.5% of the genes, some of them being direct targets
as shown by chromatin immunoprecipitation. STOX1 overexpression correlates strongly and specifically with transcriptomic
alterations in preeclamptic placentas (r=0.30, p=9.10
27). Numerous known key modulators of preeclampsia (such as
Endoglin, Syncytin, human chorionic gonadotrophin -hCG-, and Glial Cell Missing Homolog -GCM1-) were modified in these
transformed choriocarcinoma cells.
Conclusions: Our results contribute to reconcile contradictory data concerning the involvement of STOX1 in preeclampsia.
In addition, they strongly suggest that anomalies in STOX1 expression are associated with the onset of preeclampsia, thus
indicating that this gene should be the target of future studies. Our cellular model could constitute an invaluable resource
for studying specific aspects of this human disease.
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Introduction
Mutations in STOX1 were proposed to be causal for
predisposing to preeclampsia [1], a hypertensive disorder
originating from placental defects affecting up to 10% of human
pregnancies [2]. However, three recent studies have shown that
the polymorphism described in the first paper as a causal mutation
is widely shared by non-preeclamptic women from various
populations [3–5]. One of the specific features of STOX1,a s
depicted in the primary study, was its allele-specific expression
from maternal alleles, since the authors showed that STOX1
mRNA was absent in hydatiform moles, which are exclusively of
paternal origin [1]. This discovery is in concordance with the idea
that imprinted genes may be particularly involved in preeclampsia
[6]. However, this observation was challenged by the recent results
of Iglesias-Plata and co-workers, which showed by the analysis of
SNPs present in STOX1 ORF, that STOX1 is rather bi-allelically
expressed in the placenta, as well as in other tissues [4]. In the
present study, we show in a cellular model that STOX1
overexpression reproduces the transcriptional effects of preeclamp-
sia in the human placenta.
Results
We stably transfected STOX1 ORF under the control of the
CMV promoter in the JEG-3 choriocarcinoma cell line. The
choice of this cell line was dictated by two considerations; first of
all, a transformed line is a tool that can be kept and used by several
teams; second, JEG-3 cells are considered as a good model for
trophoblasts, and have been used in numerous studies on this
topic. Interestingly, JEG-3 cultures release human chorionic
gonadotrophin, human placental lactogen, progesterone, and are
able to transform steroid precursors into estrone and estradiol.
They have been profusely used to investigate molecular aspects of
trophoblast function.
Nine stable clones expressing STOX1 were obtained, with
overexpressions ranging from 2 to 30 fold, as shown by qRT-PCR.
Total RNA was prepared from the AA6 cell line (overexpressing
STOX1 30 times) and the BD3 cell line (stably transfected with the
empty pCMX vector). mRNAs were used as templates to label
cDNA that was hybridized to Affymetrix arrays (u133 2.0)
encompassing 53,000 human transcripts. The results have been
deposited as a GEO dataset, with the accession number
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3905GSE13475. Among the 53,000 transcripts, 22,980 were expressed
at a sufficient level to allow their detection and analysis. We found
that more than 2800 transcripts (,12.5%) were significantly
modified by STOX1 over expression (1840 induced –figure
1A- and 1018 repressed –figure 1B- at least two-fold).
We used the DAVID software on the groups of induced and
repressed genes (http://david.abcc.ncifcrf.gov/home.jsp) [7] to
detect Gene Ontology groups. We could show a significant excess
of transcription factors among the genes that were successfully
grouped in clusters (415 repressed (39.9%), 848 induced (46.1%),
Figure 1). Indeed, inside these groups, 168 (30%) and 255 (40.4%)
genes were related to transcription regulation among repressed
and induced genes, respectively. Among the modified transcription
factors, Zinc Finger-containing genes were very abundant (56 and
131, respectively). This proportion was highly significant com-
pared to other families of transcription factors (Table 1), and
associated with an excess of induced transcripts. Reciprocally, we
observed that a high number of Homeobox-containing genes were
down-regulated. Other analyzed families were not significantly
modified compared with the rest of the transcripts.
In addition, we used qRT-PCR on some of the stable
transformants expressing STOX1 at different levels, and obtained
an external validation of the microarray results (Figure 2). We
analyzed a subset of five induced, four repressed and four
unmodified genes. The correlation between the Log2 (induction) in
the array compared with the Log2 (induction) in the qPCR
experiment was 0.944 (Figure 2B). Despite some individual
variations between stable transformants, STOX1 overexpression
induced similar gene alterations (Figure 2A). This indicates that
the effects noticed in the two cell lines used for the microarray are
directly caused by STOX1 and not by possible general
deregulations induced by the transfection and selection procedure.
Next, we analyzed systematically the promoter composition of
transcription factors whose expression is affected by STOX1 using
Genomatix (www.genomatix.de). We contrasted the group formed
by induced (55 promoters) and repressed (39 promoters)
transcription factors with non-modified genes (49 promoters) by
a Student t-test (Supplemental Table S1). For binding sites present
on average more than once in each promoter, the forkhead
binding site (V$FKHD) was the most significant (p=0.0044) after
V$BRNF, a binding site for POU transcription factors
(p=0.0022). This observation is consistent with the idea that
STOX1 belongs to the enlarged FOX family. We then performed
ChIP experiments (four independent experiments) followed by
qPCR using primers from the promoters of genes strongly induced
by STOX1 overexpression and enriched in FKHD binding sites
(Figure 3). Thirteen different promoters corresponding to the 8
genes COL6A3, S100A4, TMEM45a, ARRDC3, TNFSF10, ALOX5,
EBI3 and PLCB1 (induced 28-, 19-, 15-, 15-, 9-, 13-, 12-, and 11
fold, respectively), were recovered using the Genomatix Gene2-
Promoter function. For several genes, multiple putative promoters
were identified by the program (up to 4 for ARRDC3) and primers
surrounding the putative forkhead binding sites were designed.
Among the thirteen putative promoters, seven were significantly
enriched after chromatin IP and corresponded to 6 genes out of 8.
In the case of ARRDC3, only one promoter was significantly
enriched by immunoprecipitation. This approach confirmed that
STOX1 binds the promoter of these genes as a transcription factor
involved in their regulation.
We then attempted to compare our microarray results with
published transcriptomic data comparing normal and preeclamp-
tic placentas. Among these few studies, only one to the best of our
knowledge was deposited as accessible GEO Profiles [8]. We
extracted the 500 genes that were the most different between
normal and preeclamptic placentas from this study. Among those,
265 (207 induced and 58 repressed in preeclampsia) were
expressed at a sufficient level to be detected in our microarray
experiment (Supplemental Table S2a). These values enabled us to
show very significant differences between the expected proportions
of induced or repressed genes if the distribution was random
(Supplemental Table S3). The data were also analyzed by a linear
regression approach (Figure 4). To achieve this, the induction ratio
of the 265 genes found to be transcriptionnally modified in the
preeclampsia study of Nishizawa and co-workers [8], were plotted
against the ratio of induction/down-regulation of the same genes
in the JEG-3 cells overexpressing STOX1. Strikingly, the
correlation applied between genes whose expression is affected
by STOX1 and preeclampsia-modified genes was highly signifi-
cant (r=0.295, p=9.8 10
27, Figure 4). Since this correlation was
made between induction/repression ratios, it is corrected for
confounding effects, such as gene expression levels for instance.
Very similar results were obtained when comparing STOX1
effects with transcriptional deregulation observed in older
transcriptomic studies dealing with syncytialisation and the links
between hypoxia and placental diseases [9,10].
As a control of the specificity of STOX1-induced transcriptome
alterations, our data were compared with a study where mid-
gestation versus normal term placentas were analyzed by
microarray analysis [11]. We also extracted the 500 most modified
genes from this study and 311 were common with the ones of our
own experiment (Supplemental table S2b). However, in this case,
no correlation could be found between the subsets of transcrip-
tionnally modified genes (r=0.02 p=0.72, Figure 4). These
observations strongly suggest that STOX1 overexpression in JEG-
3 cells reliably reproduces modifications induced by preeclampsia
in the placenta.
Discussion
Our results provide new data suggesting that STOX-1 could be
involved in the processes leading to preeclampsia. Interestingly,
among the modified genes, we found i) hCG (induced 2.25 fold for
CGA and 3.23 fold for CGB, the hCG-specific polypeptide), one
of the well-known overexpressed genes in preeclamptic placentas,
ii) endoglin (induced 2.23 fold), which is the earliest serum marker
observed as induced by preeclampsia in patients [12], iii) ERVW1
(syncitin, induced 2.03-fold), an endo-retrovirus known to be
crucial for the formation of the syncytiotrophoblast [13], as well as
iv) GCM1 (decreased 3.4-fold), known as the most specific
transcription factor for trophoblast cells [14], and specifically
down-regulated in preeclamptic placentas [15]. In addition,
overexpression of STOX1 stimulates EBI3 (612.0-fold), an
interleukin–12 p40 expressed at very high level by syncytiotro-
phoblasts and extra villous trophoblasts throughout human
pregnancy, and involved in implantation. It is presented by
HLA-G, suggesting that it is an immunomodulator, possibly
involved in NK cell regulation able to modulate proliferation and
migration processes [16; 17]
Similar to other studies [3–5] challenging the role of STOX1 in
preeclampsia, we sequenced 20 patients and 20 controls but could
not find any association with the Y153H polymorphism described
in the first study [1], neither find any transcriptional effects
differentiating normal and pathological placentas (data not
shown). We hypothesize that the reported polymorphism is in
linkage disequilibrium with the true causal mutation. It is
interesting to notice that STOX1 in mice and humans contains
a very long first intron (,50 kb), which has not been sequenced,
and could contain elements regulating the mRNA splicing, shown
STOX1 and Preeclampsia
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transcription level did not vary between normal and pathological
placentas, our results suggest that STOX1 is involved in very early
events of placental development, which could not be addressed by
analyzing term or near-term placentas. Another problem reported
by Iglesias-Plata is the non-imprinted status of STOX1 [4]. In fact,
a close examination of their sequencing data suggests that there
could be a quantitative difference in allelic expression in fetal and
placental tissues. This could be explained by cell-type heteroge-
neity of its imprinted status in the placenta. Although they also
show that the first CpG island located in the first exon is
unmethylated, other distant regulatory regions could be altered as
reported for the IGF2/H19 system.
Caution is warranted when extrapolating results obtained in a
cellular model to the general trophoblast population. However,
JEG-3 cells constitute an interesting and reliable model of
trophoblast function, as suggested by ancient and recent studies
[18]. The results of the present study, substantiate this idea, since
the main result is a strong and significant correlation between a
specific alteration of the JEG-3 transcriptome and preeclampsia-
induced transcriptional modifications in the placenta. Clearly,
while this correlation is highly significant, the rest of the variability
could be explained by the action of other pathways involved in
preeclampsia, as well as by modifications of other cell types present
in the placental villi. In this context in vitro transformation of
cytotrophoblasts into syncytiotrophoblast, as previously described
[19–22] seem to show a specific and exclusive expression of
STOX1 in the former (Rigourd et al, in preparation). It would
mean that the syncytialisation process abruptly inactivates the
expression of STOX1, the underlying mechanisms remaining
elusive. Since hypoxia, or more generally brutal variation in
oxygen pressure, are considered as major actors of preeclampsia
pathogenesis [23; 10; 24], it was interesting to match the
microarray result with HIF1a induction. However, HIF1a was
not at all modified at the transcriptional level by STOX1
overexpression. This does not disqualify an effect on the
stabilization of the HIF1a protein, which could then participate
in the gene induction effects. Also, using cDNA from placental
explants put in hypoxia, we could not see any induction of STOX1
expression (data not shown). Hypoxia-induced genes were
nevertheless found elevated in preeclampsia [10], and were
significantly correlated with gene-induction in the JEG-3 cells
overexpressing STOX1 (present study). Therefore, the link between
hypoxia and STOX1 exists, but probably in a subtle form. In
conclusion, our study indicates that STOX1 deserves further
investigation for its role in the aetiology of preeclampsia.
Materials and Methods
Patients and ethics
All the placentas from the patients were collected from four
Parisian maternities (Cochin, St Antoine, Institut de Pue ´riculture
and St Vincent de Paul). This study was approved by the Ethics
Committee of Paris Cochin (France), CCPPRB (Comite ´ Con-
sultatif de Protection des Personnes dans la Recherche Biome ´di-
cale). All patients have given their written consent for the use of
their placenta. Placentas were obtained from caesarean section
outside labor from healthy mothers.
Placental villi and cytotrophoblast purification
Biopsy samples were rapidly collected at six to ten various
locations from each placenta between the decidual and chorionic
plates. Villous tissue was dissected free of fetal membranes, vessels
and tissue from maternal origin, rinsed and minced in Ca
2+,M g
2+
free Hank’s Balanced Salt Solution (HBSS). Cytotrophoblast cells
were prepared using standard procedures of negative selection
mastered in the laboratory [19–22].
Plasmid constructions
The STOX1A construct was a generous gift of Dr C.B.
Oudejans (VU University Medical Center, De Boelelaan 1117,
1081 HV, Amsterdam, The Netherlands). The ORF was isolated
and subcloned in the pCMX expression vector and resequenced.
Three mutations were found (ARC in 1658 (GAA=GluRG-
CA=Ala), a deleted T in 2948 (which creates an early stop codon),
and the initiation codon (ACG (THR) instead of ATG (MET)) and
corrected by site-directed mutagenesis. Hence we obtained a
pCMX vector containing the coding region of STOX1-A.
Cell culture and stable transfection
JEG-3 choriocarcinoma cells were seeded in DMEM medium
(Gibco) supplemented with 10% FBS and 1% penicillin/
streptomycin at a concentration of 1.0610
6 cells per T25 culture
flask. At the time of transfection cells were at 60% confluence.
Cells were transfected using LipofectaminH Reagent (Invitrogen),
Figure 1. Fonctional clustering of genes modified by STOX1 overexpression (a total of 1840 induced genes and 1018 repressed
genes) were distributed in clusters using the DAVID website [7]. Interestingly, the major cluster was in both cases composed of transcription
factors, among which a majority of Zinc Finger Proteins was found. Only the significant clusters (according to the threshold defined in Material and
Methods are represented), and are classified by decreasing significance (clockwise).
doi:10.1371/journal.pone.0003905.g001
Table 1. Transcriptional factors modified by STOX1 overexpression.




decrease) Unchanged Chi2 test
ZNF-related 127 26 774 6.9 10
210
FKHD-related 4 4 30 0.064
Homeobox-containing 4 8 63 0.009
SOX-related 0 0 12 186
TATA-related 1 3 40 0.122
All transcriptome 1840 1018 20 122
doi:10.1371/journal.pone.0003905.t001
STOX1 and Preeclampsia
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pCMX-STOX1-A or 4 mg empty pCMX together with 0.4 mgo f
PGK neo (the PGK-neo expression vector was a kind gift of Dr
Djian [25]) per T 25 cm
2 culture dish with Opti-MEMH I
Reduced Serum Medium. This plasmid ratio is known to ensure a
co-transfection by both plasmids when the cells become resistant.
Cells were passaged at 1:10 dilution into selective medium
72 hours post transfection. Selection was continuously applied
using Geneticin (G-418) (Invitrogen) at 500 mg/ml concentration
for approximately 3 weeks. Resistant clones (9 cell lines transfected
with pCMX-STOX1-A and 3 cell lines transfected with empty
pCMX) were grown individually in continual selection and used
for further analysis or frozen in DMSO.
RNA Extraction and cDNA synthesis
Total RNA was extracted from 12 differents clones using
Trizol Reagent (Invitrogen) in accordance with the manufacter’s
instruction. cDNA synthesis was performed using Superscript
cDNA synthesis kit (Invitrogen).
Quantitative RT-PCR
q RT PCR was performed using a Light Cycler (Roche) and the
Invitrogen kit (SYBRH). The primers for STOX1 cDNA
amplification were: 59-TTGGGTGTGAA-39,5 9-TTGGAGC
GTTTGATGAAACA-39. The clone with the highest STOX-1A
overexpression (AA6) and a negative clone (BD3) were selected by
RT-PCR with SDHA as reference gene. The primer couples for
Figure 2. (A) Comparison of four cell lines overexpressing STOX1 for a series of 13 genes known to be modified by the microarray experiment, by
quantitative RT-PCR. Five genes were overexpressed (PTGDS, ALOX5, TNFSF10, bARRESTIN, TMEM45a), four down-regulated (ANXA3, ZNF22, APOA2,
FAM43A) and four mildly induced or unmodified (ANKRD28, PGM2L1, DNAJC10, LONP1). The diagram shows a fairly good reproducibility of the gene
alterations whatever the cell line overexpressing STOX1. The expression level of STOX1 is represented in the first series of histograms. (B) Comparison
of the expression levels of the microarray and of the qRT-PCR results for the same series of 13 genes. For AA6, the cell line from which the cDNA
hybridized on the microarrays was obtained, the correlation is excellent (R=0.944). For the second line AB1, overexpressing STOX1 at a milder level,
the correlation is also very good (R=0.829). In this case, the overall expression is nevertheless lower as shown by the linear regression. This suggests
that at least in some cases, the deregulations induced by STOX1 overexpression are somehow proportional to this overexpression.
doi:10.1371/journal.pone.0003905.g002
Figure 3. Thirteen promoters encompassing putative binding sites for Forkhead containing transcription factors were quantified
by qPCR after Chromatin Immunoprecipitation, using a novel anti-STOX1 polyclonal antibody. For several genes alternative putative
promoters were identified by Genomatix, and only some of the promoters appeared enriched. This is clearly the case for ARRDC3, for which promoter
P4 was considerably and exclusively enriched (17.5 fold compared to control). Some other targets were only mildly enriched such as the TNFSF10
promoter. The results are the mean of four independent ChIP experiments on which three qPCR assays have been performed.
doi:10.1371/journal.pone.0003905.g003
STOX1 and Preeclampsia
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Gene expression array
5 micrograms of cDNA of AA6 and BD3 clones were sent to
Affymetrix type IVT3 expression array platform. cDNA and
labeling for hybridization scanning and data normalization were
performed by the platform, which provided the final data.
Standard quality control procedures were performed and
validated (available upon request). Data have been sent to a
public database upon acceptance of the study for publication (GSE
13475 and summarized as supplemental data, Supplemental Table
S4).
Bioinformatics
Putative transcription factor binding sites were identified by
statistical analysis (Student t-test, followed by Bonferronni
correction for multiple testing) using the Gene2Promoter option
of Genomatix (Genomatix.de). Functional clustering was per-
formed using the DAVID database. The groups are clusterized
according to common keywords, enabling to define a p-value of
the occurrence of the keyword in a specific group of genes inside
the set of genes submitted, compared with the total gene content.
The calculated enrichment score is the harmonic mean of the
inverse of these p-values. Since random groups of genes are also
able to generate enrichments, a simulation was performed with
random groups of genes which enabled to define a threshold for
Figure 4. Linear regression analysis comparing the induction/repression ratio of the genes from the present study (comparing JEG-
3 cells overexpressing STOX1 with mock-transfected JEG-3 cells) with induction ratio of two other transcriptomic studies on the
placenta. The first external study, performed by Nishizawa and coworkers [8] compared 4 normal and 10 preeclamptic placentae. The 500 most
modified genes from this article were obtained, and 265 were detectable among the genes identified here. The induction/repression ratio of the 265
genes are plotted (horizontal axis, blue diamonds) against the same genes of the present work (vertical axis). In this case, the correlation was highly
significant between the two sets of induction ratio (r=0.30, p,0.000001). As a control, another study on placental transcriptomics was used, which
compares mid gestation and term placentas [11]. Again, the 500 most modified genes were selected and 311 were detectable among the genes
identified in the present study. Their induction/repression ratio are represented along the horizontal axis as red squares. In this case, the correlation
was very close to 0 (r=0.02, p=0.72). These results demonstrate that STOX1 overexpression in choriocarcinoma reproduces with fidelity several
aspects of the preeclamptic disease despite the much higher complexity of the placenta.
doi:10.1371/journal.pone.0003905.g004
STOX1 and Preeclampsia
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groups of randomly selected genes (50 to 3000 genes) were
introduced in the ‘‘upload’’ window of the DAVID website and
submitted to functional clustering. We could observe that the
number of clusters obtained by this approach increased with the
number of genes in a linear fashion. Furthermore, the
enrichment score calculated for the first cluster obtained (the
highest), increased steadily with the number of genes introduced.
We could derive a linear equation (Highest enrichment
score=0.0026Number of genes +0.4718, R
2=0.84) able to
predict the highest score from random data. This information
was used to select gene clusters that present an enrichment score
above this value.
Characterization of an anti-rabbit polyclonal STOX1
antibody
A novel polyclonal antibody was generated using two peptides
(EP053592: AcNH-GGR AVF RAF RRA NAR C-CONH2,
EP053593 H2N-CDL KPS QTG PKE KPF Q-CONH2) injected
in rabbits by Eurogentec (Belgium). This antibody was validated
by Western blot and by immunohistochemistry staining. The
specificity was assessed using the two free peptides as competitors.
Specific bands corresponding to three STOX1 isoforms were
detected. In vitro synthesis and labeling experiments using the three
main STOX1 (A, B, C) isoform-coding plasmids as templates
indicated that the bands detected by the antibody in placenta and
JEG-3 cell extracts correspond to these three isoforms.
Chromatin Immunoprecipitation adapted from [27] JEG-
3 cells were seeded at a concentration of 1.0610
6 cells per T25
culture flask. The initial step is the crosslinking of the live cells with
formaldehyde. Cells were then lysed (Buffer containing HEPES,
NaCl, EDTA, Triton, EGTA, SDS and Protease inhibitor
cocktail) and released chromatine fragments were sheared by
sonication to generate DNA fragments of ,200 bp. Specific
immunoprecipitated factors together with crosslinked DNA were
immunoprecipitated at +4uC after an 1 hour incubation with pre-
immune serum and a preclearing step with a 50% salmon sperm/
BSA/ProteinA beads slurry. Anti-rabbit polyclonal STOX1
antibody at 1/100 concentration was used overnight for
immunoprecipitation. Finally, protein-DNA crosslink in the
immunoprecipitated (IP) material was reversed and the DNA
fragments purified. If the STOX1 protein was associated with a
specific genomic region in vivo, DNA fragment from this region
should be enriched in IP compared to the other portion of the
genome.
QPCR validation
The presenceand quantification ofrelevant genomicregion inthe
IP is determined by qPCR in which the immunoprecipitated
material was used as a template for simultaneous amplification with
gene specific primers and from a reference region (micro satellite
DXS 118). The screening of 8 genes (up to 4 putative promoters for
ARRDC3) affected by STOX1 overexpression and containing
FKKD putative binding sites in their promoter was performed.
The primers were designed by using Primer-3 software (http://
frodo.wi.mit.edu/cdi-bin/primer3/primer3-www.cgi. For qPCRs,
we used the Absolute QPCR SYBRH green mix (ABgene) and the
Roche Light-Cycler PCR apparatus. Results obtained with the
precipitated DNA were compared to those from input DNA
samples.
Supporting Information
Table S1 Promoter analysis. Comparison of the promoter
content in Transcription factor binding sites betwwen STOX1-
modified and STOX-1 unmodified genes
Found at: doi:10.1371/journal.pone.0003905.s001 (0.21 MB
XLS)
Table S2 Table S2A and S2B: Data for correlation analysis
transcriptomic data from two experiments (effects of preeclampsia,
and effect of gestation time) compared with STOX1 effects
Found at: doi:10.1371/journal.pone.0003905.s002 (0.24 MB
XLS)
Table S3 Observed versus expected between Stox1 overex-
pressed genes and 265 genes strongly modified in pre-
eclamptic placentas (According to Nishizawa et al, 2007).
Statsitical comparisons (Chi2 tests) for modified categories of
genes at three threshold between preeclampsia effects and STOX1
overexpression effects
Found at: doi:10.1371/journal.pone.0003905.s003 (0.02 MB
XLS)
Table S4 AA6 column corresponds to the cells overexpressing
STOX1. BD3 to the control cells transfected with empty pCMX
vector
Found at: doi:10.1371/journal.pone.0003905.s004 (4.43 MB
XLS)
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